More news and press

Accelerating Forward Engineering at Genome Scale
Harnessing the power of biology to create products of commercial and scientific value is a challenging problem. The goal of reducing biological…
Read More
Single Cell Writing May Unlock CRISPR’s Full Potential
After over three years of super stealth mode, Inscripta gave its first public presentation today at the 2019 Synthetic Biology: Engineering,…
Read More
Inscripta Looks to Combine CRISPR, Single-Cell Genomics, Synthetic Biology in New Platform
Kevin Ness, the CEO of gene editing company Inscripta, has long had a vision of doing for genome writing what Illumina did for…
Read More
Inscripta’s MAD7 Named a Top Innovation of 2018 by The Scientist
The award recognizes products that are set to revolutionize research and advance scientific knowledge
Read More
Inscripta Wins Rising Star Award from Colorado BioScience Association
Inscripta has been selected for the Colorado BioScience Association’s 2018 Rising Star Award
Read More
Do CRISPR Risks Outweigh Rewards?
We’ve become accustomed to new headlines about CRISPR nearly every week, touting gene editing’s potential to transform…
Read More
Meet the Startup That's Giving Away Its CRISPR-Like Technology for Free
CRISPR is one of the most promising areas in biotech, but much of that potential has been locked behind expensive licensing…
Read More
Inscripta Looks to Become the Illumina of Genome Editing Technology Firms
Inscripta is creating its own market and customer base while also utilizing the expertise of its customers to refine…
Read More
Gene-editing startup Inscripta raises $55.5 million
Inscripta said on Wednesday it raised $55.5 million in funding as the privately held biotech startup looks to strengthen…
Read More
This Startup Wants to Democratize CRISPR Gene Editing Research by Making It Free
CRISPR gene editing is widely regarded as one of the most significant advances in the life sciences in decades…
Read More
2 of 3